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Abstract
Background: Several polymorphisms within the renin-angiotensin system cluster of genes have
been associated with the advent of coronary artery disease (CAD) or related pathologies. We
investigated the distribution of 5 of these polymorphisms in order to find any association with CAD
development and distinguish if any of the biochemical and behavioural factors interact with genetic
polymorphisms in the advent of the disease.
Methods: ACE I/D (rs4340), ACE A11860G (rs4343), AT1R A1166C (rs5186), AGT T174M (rs4762)
and AGT M235T (rs699) gene polymorphisms were PCR-RFLP analysed in 298 CAD patients and
510 controls from Portugal. Several biochemical and behavioural markers were obtained.
Results: ACE I/D DD and ACE11860 GG genotypes are risk factors for CAD in this population.
The simultaneous presence of ACE I/D I and ACE11860 A alleles corresponds to a significant trend
towards a decrease in CAD incidence. We found several synergistic effects between the studied
polymorphisms and classical risk factors such as hypertension, obesity, diabetes and dyslipidaemia:
the presence of the DD genotype of ACE I/D (and also ACE11860 GG) increases the odds of
developing CAD when associated to each one of these classical risk factors, particularly when
considering the male and early onset CAD subgroup analysis; AGT235 TT also increases the CAD
risk in the presence of hypertension and dyslipidaemia, and AT1R1166 interacts positively with
hypertension, smoking and obesity.
Conclusion: ACE polymorphisms were shown to play a major role in individual susceptibility to
develop CAD. There is also a clear interaction between RAS predisposing genes and some
biochemical/environmental risk factors in CAD onset, demonstrating a significant enhancement of
classical markers particularly by ACE I/D and ACE11860.
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Cardiovascular diseases represent today the main cause of
death in human adults in western populations. A reason-
able number of studies have focused in testing specific
genetic markers among groups of ischemic coronary artery
disease (CAD) patients and control groups, aiming to find
a correlation between these gene polymorphisms and dis-
ease. The renin-angiotensin system (RAS) has been shown
to play a key role in the regulation of blood pressure and
influence the cardiovascular system [1], and several genes
belonging to this system have been associated with CAD.
Two of the most intensively investigated genetic polymor-
phisms are the insertion/deletion (I/D) alleles of the angi-
otensin I-converting enzyme (ACE) gene and mutations at
the angiotensin II AT1 receptor. Several mutations at the
angiotensinogen (AGT) gene have also been studied as
candidates in essential hypertension [2,3] or myocardial
infarction (MI) [4].
Albeit all these and other markers that have been identi-
fied in latter years as possible risk factors for several
pathologies associated to CAD, a considerable number of
opposing results also exist. The DD genotype of ACE for
instance has been found to be linked to MI [5,6] but con-
trary reports also exist [7,8]. There are even conflicting
reports on the assessment of risk profiles depending on
the populations studied [6,9]. The AT1R A1166C poly-
morphism has also been subjected to opposite reports as
to its role in CAD, particularly when it is related to the
patient's geographic origin: it was found to be signifi-
cantly associated with CAD in Caucasians [9,10] but not
in Asians [11]. The AGT M235T polymorphism has been
shown to be positively related to essential hypertension
[12] and MI [9] but other studies found no relation at all
between the marker and disease [13,14] and few reports
exist to confirm an association with plasmatic AGT con-
centration level [14].
In this report we have studied the distribution of geno-
typic and allelic frequencies at 5 loci, in two groups of
individuals from Madeira Island (Portugal), an island set-
tled mainly by the Portuguese. A group of patients with a
known CAD history and a control group with no CAD
related pathologies were selected. The main focus was to
analyse these genetic polymorphisms, alone or combined
in haplotypes, and clarify their potential association with
CAD related conditions. Knowing that in most cases CAD
has a multifactorial basis, involving a number of genes
and environmental factors interacting to determine
whether or not the disease will develop, we also tried to
determine a possible interaction between the five gene
polymorphisms and several well known CAD linked fac-
tors.
Methods
The total population of this study consisted of 808 Cauca-
sian individuals (aged between 18 and 70 years old)
divided in two groups: 510 subjects without a history of
CAD, MI, or stroke – excluded after a medical examina-
tion and interview – randomly selected from the electoral
rows, who participated as controls, plus 298 individuals
recruited from patients admitted to the Cardiology Care
Unit of the Main Hospital of Funchal (Hospital Central
do Funchal, Madeira Island, Portugal). Patients' recruit-
ment satisfied the following criteria: stable coronary dis-
ease suggested by clinical analysis and proved by
angiographic exam (a significant lesion was considered
when ≥ 75% of luminal narrowing was observed in at
least one of the major arteries) or occurrence of MI as
defined by the WHO criteria. This investigation is in con-
formity with the principles outlined in the Declaration of
Helsinki and was approved by the Hospital's Ethics Com-
mittee; all subjects gave their informed consent. Cases and
controls filled in a questionnaire about their personal his-
tories – age, sex, essential hypertension, diabetes mellitus,
smoking habits, overweight, sedentary habits, alcohol
ingestion and family medical history – and provided
blood samples for genotype analysis and biochemical
measurements. The presence of traditional risk factors in
both groups was determined using the criteria standard-
ized by the European Society of Cardiology: an hyperten-
sive condition was attributed when systolic blood
pressure values were ≥ 139 mm Hg and/or diastolic blood
pressure values ≥ 89 mm Hg in at least two separate meas-
urements or when being medicated against hypertension;
subjects were considered smokers when consuming more
than five cigarettes per day or non-smokers when never
smoked or had stopped smoking at least one year before
sample collection; obesity was defined for BMI values ≥ 30
kg/m2; dyslipidaemia was considered for plasmatic values
of total cholesterol ≥ 200 mg/dl, triglycerides ≥ 150 mg/dl,
LDL ≥ 130 mg/dl and HDL ≤ 40 mg/dl. Table 1 gives the
basic characteristics of the studied population.
Genetic and biochemical analyses
Genomic DNA was extracted from an 80 μl aliquot of
whole blood using standard phenol/chloroform method-
ologies with ethanol precipitation. The ACE I/D gene alle-
les (D and I) were identified by PCR amplification as
previously described [15]. In order to reduce mistyping of
ID heterozygotes as DD homozygotes, a re-amplification
was carried out in all identified DD homozygotes using an
internal primer specific for the I allele [15]. The other
SNPs were identified following previously established
PCR-RFLP conditions: AT1R A1166C [16], AGT M235T
[17], AGT T174M [18] and ACE A11860G [19]. Amplifi-
cation and digestion results were submitted to electro-
phoresis in silver stained T9C5 polyacrilamide gels.Page 2 of 12
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In order to analyze the relative influence of genotypes and
biochemical parameters among gender, the two groups
(controls and patients) were each subdivided into male
and female subgroups. Further grouping according to age
(45 or less years old) was performed, aiming to analyse
the association between genetics and early onset CAD.
Individuals aged ≥ 45 years were not included in this sub-
analysis because no data about the age of CAD onset was
obtained. Basic genetic parameters such as allele and gen-
otype frequencies at each locus, proportion of individual
heterozygous samples (direct count heterozygosity as well
as the unbiased estimate) and population differentiation
were calculated using Genepop v3.1d [20] and Arlequin
[21]. Haplotype frequencies were calculated using the
PHASE 2.0 software [22]. The overall genetic diversity,
within each group diversity and the amount among
groups were also calculated. Deviation from Hardy-Wein-
berg equilibrium per population and locus was calculated
according to Weir and Cockerham FIS estimator using
FSTAT v.2.9.3., with a Bonferroni correction for all signif-
icance levels [23]. Within all groups of subjects, distribu-
tion of allele and genotype frequencies and their
differences were calculated using χ2 tests. Associated prob-
abilities (P) were calculated applying Fisher's exact test
adjusted for multiple comparisons of associated geno-
types. To test the significance of association between gen-
otypes at pairs of loci in each sample we used a log-
likelihood ratio G-statistic as implemented in Genepop.
The relative odds ratio (OR) and 95% confidence interval
of relative CAD risk for any of the genetic polymorphisms
and biochemical and behaviour markers, was assayed by
logistic regressions using the SPSS package. To analyse
possible positive or negative interactions between classi-
cal risk factors of CAD and genetic polymorphisms we
used a 4 × 2 table approach and epiInfo 3.4.3 to calculate
ORs, respective 95% confidence intervals and two-tailed p
values, as well as synergy measures in additive (SI) and
multiplicative models (SIM) [24-26]. It was assumed that
unexposed individuals without the susceptibility geno-
type have a certain background risk for disease (OR00 is
assumed to be 1); OR10 refers to the relative risk for dis-
ease among people without the susceptibility genotype
for disease but exposed to the environmental risk factor
relative to those with neither the susceptibility genotype
nor exposure; OR01 refers to the relative risk among peo-
ple with the susceptibility genotype who are not exposed
to the risk factor relative to those with neither the suscep-
tibility genotype nor exposure; OR11 is the ratio of disease
risk among exposed people with susceptibility genotype
to diseased risk among unexposed people without the sus-
ceptibility genotype. These ORs were then used in the cal-
culation of synergy indexes: SI = (OR11-1)/(OR10+OR01-
2), SIM = OR11/(OR10 × OR01) [25,26]; the relative excess
risk due to interaction, RERI = OR11-OR10-OR01+1 [26];
and the attributable proportion of the disease due to inter-
action, AP = RERI/OR11 [26].
Results
Classical risk factors
As expected, both the control and patient group showed
differences in the biochemical markers and other conven-
tional risk factors analysed (Table 1). Systolic and diasto-
lic blood pressure, dyslipidaemia, arterial hypertension,
Table 1: Baseline characteristics and clinical data for conventional risk factors
Control CAD P
n 510 298
Gender (Male/Female, %) 57.84/42.16 78.86/31.82 ***
Age (years, mean) 47.47 ± 12.55 54.96 ± 10.40 ***
Familiar CAD history (%) 12,16 56,04 ***
Sedentarism (%) 61.96 58.39 NS
Smoking habit (%) 26.86 38.93 ***
Systolic blood pressure (mm Hg) 127.54 ± 17.43 134.63 ± 20.43 ***
Diastolic blood pressure (mm Hg) 75.83 ± 10.69 79.10 ± 10.46 ***
Arterial hypertension (%) 22.35 58.72 ***
PWV (m/s) 8.80 ± 1.89 10.26 ± 2.13 ***
Body mass index (kg/m2) 26.41 27.80 ***
Glycaemia (mg/dl) 97.96 ± 24.47 119.94 ± 50.60 ***
Diabetes mellitus (%) 3.14 23.15 ***
Total cholesterol (mg/dl) 217.72 ± 44.73 205.39 ± 48.14 **
HDL (mg/dl) 57.15 ± 17.04 39.74 ± 9.75 ***
LDL (mg/dl) 114.70 ± 37.27 119.02 ± 44.08 NS
Triglycerides (mg/dl) 130.73 ± 85.71 192.97 ± 142.96 ***
Dyslipidaemia (%) 11.76 70.81 ***
Values presentation: mean ± SD; *P < 0.05, **P < 0.005, ***P < 0.0001, NS not significant P > 0.05; PWV, pulse wave velocity; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein.Page 3 of 12
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CAD in the family are much higher in CAD patients then
in controls. In average, LDL was also higher in the CAD
group and HDL values were lower in the patients group,
as well as total cholesterol. We performed a multivariate
logistic regression analysis using the variables included in
table 1 and also the putative risk genotypes of RAS poly-
morphisms. We found HDL (OR = 0.91 95%CI: 0.89–
0.93, p < 0.0001), glycaemia (OR = 1.01 95%CI: 1.01–
1.02, p < 0.0001), CAD history (OR = 2.14 95%CI: 1.36–
3.35, p = 0.001), smoking habit (OR = 1.81 95%CI: 1.11–
2.93, p = 0.017), dyslipidaemia (OR = 13.18, 95%CI:
8.32–22.14, p < 0.0001) and ACE I/D DD polymorphism
(OR = 1.72, 95%CI: 1.08–2.75, p = 0.022) to be inde-
pendently related to CAD.
Allele and genotype distribution
Table 2 presents the distribution of genotypes for the 5
loci in controls and patients. Genotypes at both ACE loci
show statistically different distributions for both the over-
all analysis and male subgroup. Only the group of
patients is in Hardy-Weinberg equilibrium at each locus
and overall as the control group is not at HWE at locus
ACE I/D (χ2df1 = 7.55, P < 0.01). As expected, mutations
at the AGT and ACE loci show strong significant linkage
disequilibrium within each gene (P < 0.0001) for both
groups, even after Bonferroni correction. The group of
patients also shows significant genotypic disequilibrium
at AGT235/AT1R (P < 0.03). An exact G-test for popula-
tion differentiation gave an overall value of 0.00238 in
which the loci contributing significantly to the differenti-
ation between the two samples are both ACE polymor-
phisms (χ2 test, P < 0.0001 and P < 0.01 for ACE I/D and
ACE11860, respectively). Thus taking in consideration all
loci combined, both populations are significantly differ-
ent concerning the genic differentiation (χ2 df10 = 24.082,
P = 0.007).
Male patient and control groups show significant differ-
ences in allele content at both ACE I/D and ACE11860
loci (P < 0.0001 and P < 0.05, respectively). This is also
reflected on the distribution of genotypes across ACE I/D
which is highly significant in a G-like test (P < 0.003).
Analysing possible genotype associations of ACE poly-
morphisms and CAD development we obtained signifi-
cant results when testing ACE I/D DD and ACE11860 GG,
while ACE I/D ID genotype showed to decrease CAD risk
(Table 3). The male population analysis resulted even
more significant for these polymorphisms and no signifi-
cant results where found in the female subgroup. ACE I/D
DD genotype was shown to increase the risk of early onset
CAD.
Haplotype analysis
Within the ACE gene, the haplotype ACE11860 A/ACE I/
D I was found to provide a decreased risk of developing
CAD, except for the ≤ 45 subgroup analysis. An associa-
tion between ACE11860 G/ACE I/D D and CAD was
found in the whole population and male subgroup anal-
ysis, while ACE11860 G/ACE I/D I was associated with the
disease in females (Table 3). No association was found
when analysing the AGT gene haplotypes (results not
shown). Considering all genes involved in the RAS sys-
tem, only five out of nineteen obtained combinations
yielded significant associations with CAD (Table 3), espe-
Table 2: Distribution of genotypes between patients and controls
Genotype Whole population (n = 808) Males (n = 530) Females (n = 278) ≤ 45 subgroup (n = 275)
CAD 
(n = 298)
Control 
(n = 510)
P CAD 
(n = 235)
Control 
(n = 295)
P CAD 
(n = 63)
Control 
(n = 215)
P CAD 
(n = 64)
Control 
(n = 111)
P
AGT235 MM 86(28.86) 148(29.02) NS 63(26.81) 87(29.49) NS 23(36.51) 61(28.37) NS 19(29.69) 63(29.85) NS
MT 155(52.01) 275(53.92) 124(52.77) 155(52.54) 31(49.21) 120(55.81) 31(48.44) 111(52.61)
TT 57(19.13) 87(17.06) 48(20.42) 53(17.97) 9(14.28) 34(15.81) 14(21.87) 37(17.54)
AGT174 TT 235(78.86) 400(78.43) NS 185(78.72) 229(77.63) NS 50(79.36) 171(79.53) NS 47(73.44) 160(75.83) NS
TM 59(19.80) 107(20.98) 46(19.57) 65(22.03) 13(20.63) 42(19.53) 16(25.00) 48(22.75)
MM 4(1.34) 3(0.59) 4(1.70) 1(0.34) 0(0) 2(0.93) 1(1.56) 3(1.42)
AT1R1166 AA 175(58.72) 291(57.06) NS 137(58.30) 179(60.68) NS 38(60.32) 112(52.09) NS 35(54.69) 110(52.13) NS
AC 106(35.57) 193(37.84) 84(35.74) 104(35.25) 22(34.92) 89(41.40) 24(37.50) 86(40.76)
CC 17(5.70) 26(5.10) 14(5.96) 12(4.07) 3(4.76) 14(6.51) 5(7.81) 15(7.11)
ACE I/D II 38(12.75) 84(16.47) ** 29(12.34) 47(15.93) *** 9(14.29) 37(17.21) NS 8(12.50) 33(15.64) NS
ID 137(45.97) 282(55.29) 108(45.96) 178(60.34) 29(46.03) 104(48.37) 28(43.75) 119(56.40)
DD 123(41.28) 144(28.24) 98(41.70) 70(23.73) 25(39.68) 74(34.42) 28(43.75) 59(27.96)
ACE11860 AA 54(18.12) 113(22.16) ** 41(17.45) 65(22.03) * 13(20.63) 48(22.33) NS 11(17.19) 43(20.38) NS
AG 135(45.30) 255(50.00) 109(46.38) 155(52.54) 26(41.27) 100(46.51) 28(43.75) 111(52.61)
GG 109(36.58) 142(27.84) 85(36.17) 75(25.42) 24(30.10) 67(31.16) 25(39.06) 57(27.01)
Values presentation: n(relative frequencies%); *P < 0.05, **P < 0.005, ***P < 0.0001, NS not significant P > 0.05.Page 4 of 12
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ACE11860 A/ACE I/D I/AGT174T/AGT235 M/AT1R A
combination and an increased probability of early onset
CAD provided by ACE11860 G/ACE I/D D/AGT174 T/
AGT235T/AT1R A.
Interaction between RAS polymorphisms and classical risk 
factors
The analysis of the possible positive/negative association
between genotypes and classical risk factors is expressed in
Tables 4 and 5, except for polymorphism ACE11860 GG,
which rendered highly similar results to the ACE I/D anal-
ysis, so the results are not shown, and AGT174, with insuf-
ficient polymorphic data to perform this analysis.
Regarding AGT235 TT or AT1R CC, we analysed only the
whole population data, because the subdivision in sex or
age classes rendered insufficient number of individuals to
perform statistical analysis. Regarding the conventional
risk of subjects unexposed to both classical risk factor and
genetic risk (reference category) as being 1.0, the OR esti-
mating the effect of joint exposure to hypertension and
ACE I/D DD, AGT235 TT or AT1R CC was significantly
higher than the ORs estimating the effect of each factor in
the absence of the other. The synergy index in early onset
CAD analysis (ACE I/D DD) was above 9, indicating a
departure from an additive relation. In this group the pro-
portion of CAD attributable to the interaction of hyper-
tension and ACE I/D DD was as high as 85%. The
genotypes AT1R CC in the overall analysis, or ACE I/D DD
in all subgroups, interact with smoking habit to develop
CAD, showing more than a multiplicative effect in
females (SI = 0.86, SIM = 1.77, AP = 0.13). The risk pro-
vided by obesity was found to be positively reinforced by
AT1R CC in the whole population analysis and ACE I/D
Table 3: Allele, genotype and haplotype association between ACE polymorphism and CAD and RAS combined set of alleles 
association with CAD
Whole population Males Females ≤ 45 subgroup
Allele
ACE11860 G 1.312(1.07–1.60)** 1.387(1.09–1.77)** NS NS
ACE I/D D 1.414(1.15–1.74)*** 1.562(1.22–2.00)*** NS NS
Genotype
ACE11860 GG 1.560(1.16–2.11)** 1.713(1.18–2.49)** NS NS
ACE I/D DD 1.795(1.34–2.41)*** 2.283(1.57–3.31)*** NS 1.880(1.05–3.36)*
ACE haplotype (ACE11860/ACEI/D)
A/I 0.670(0.54–0.83)*** 0.660(0.51–0.85)** 0.653(0.43–1.00)* NS
CAD = 191, C = 425 CAD = 155, C = 251 CAD = 39, C = 175 CAD = 42, C = 179
A/D 1.526(1.03–2.27)* NS 2.434(1.20–4.94)* NS
CAD = 47, C = 55 CAD = 35, C = 34 CAD = 14, C = 21 CAD = 8, C = 18
G/I NS NS 8.372 (2.13–32.87)** NS
CAD = 20, C = 23 CAD = 12, C = 21 CAD = 7, C = 3 CAD = 3, C = 6
G/D 1.256(1.03–1.53)* 1.440(1.13–1.84)** NS NS
CAD = 335, C = 520 CAD = 269, C = 283 CAD = 66, C = 231 CAD = 75, C = 219
RAS combined set of alleles1(ACE11860/ACEI/D/AGT174/AGT235/AT1R)
A/I/T/M/A 0.698(0.53–0.93)* 0.663(0.50–0.88)** NS NS
CAD = 76, C = 179 CAD = 96, C = 164
A/I/T/T/A 0.727(0.55–0.97)* NS NS NS
CAD = 76, C = 173
A/D/M/T/A NS 3.804(1.02–14.13)* NS NS
CAD = 9, C = 3
A/I/M/T/C 0.324(0.11–0.95)* NS NS NS
CAD = 4, C = 20
G/D/T/T/A 1.459(1.06–2.02)* 1.400(1.01–1.95)* NS 2.468(1.21–5.04)*
CAD = 71, C = 88 CAD = 87, C = 82 CAD = 14, C = 20
Values presentation: OR(95% CI); *P < 0.05, **P < 0.005, ***P < 0.0001, NS not significant P > 0.05; CAD, number of CAD patients; C, number of 
control subjects.
1Only combined set of alleles present in more than 10 individuals and yielding significant results are shown.Page 5 of 12
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AP = 0.21
30 135 1
–2.27)NS 22 55 1.80(0.91–3.55)NS
–4.39)NS 6 17 1.59(0.51–4.77)NS
–10.24)* 6 4 6.75(1.56–30.78)*
 = 1.60; SI = 4.13; SIM = 2.36; RERI = 4.36; 
AP = 0.65B
M
C
 
C
a
r
d
i
o
v
a
s
c
u
l
a
r
 
D
i
s
o
r
d
e
r
s
 
2
0
0
8
,
 
8
:
1
5
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
2
6
1
/
8
/
1
5
Table 4: Synergistic effect of ACE I/D DD genotype and classical risk factors in CAD patients and controls
Classical risk
factor
ACE I/D DD Whole population Males Females
CAD Control OR
(95%CI)
CAD Control OR
(95%CI)
CAD Control O
(95%
Hypertension
0 0 63 256 1 54 143 1 9 113 1
0 1 43 99 1.76(1.10–2.84)* 39 43 2.40(1.36–4.25)** 4 56 0.90(0.22
1 0 112 110 4.14(2.78–6.17)*** 83 82 2.68(1.69–4.25)*** 29 28 13.00(5.16
1 1 80 45 7.22(4.46–11,73)*** 59 27 5.79(3.22–10.46)*** 21 18 14.65(5.33
SI = 1.59; SIM = 0.99; RERI = 2.32; 
AP = 0.32
SI = 1.56; SIM = 0.90; RERI = 1.71; 
AP = 0.30
SI = 1.15; SIM = 1.25; RERI
AP = 0.12
Smoking
0 0 112 269 1 76 153 1 36 116 1
0 1 70 104 1.62(1.09–2.39)* 48 47 2.06(1.23–3.45)* 22 57 1.24(0.64
1 0 63 97 1.56(1.04–2.34)* 61 72 1.71(1.07–2.71)* 2 25 0.26(0.04
1 1 53 40 3.18(1.95–5.21)*** 50 23 4.38(2.40–8.02)*** 3 17 0.57(0.12
SI = 1.85; SIM = 1.26; RERI = 1.00; 
AP = 0.31
SI = 1.91; SIM = 1.24; RERI = 1.61; 
AP = 0.37
SI = 0.86; SIM = 1.77; RERI
AP = 0.13
Obesity
0 0 126 295 1 99 180 1 27 115 1
0 1 88 122 1.69(1.18–2.42)** 72 59 2.22(1.42–3.46)** 16 63 1.08(0.51
1 0 49 71 1.62(1.04–2.51)* 38 45 1.54(0.91–2.60)NS 11 26 1.80(0.73
1 1 35 22 3.72(2.03–6.87)*** 26 11 4.30(1.93–9.71)*** 9 11 3.48(1.18
SI = 2.07; SIM = 1.36; RERI = 1.41; 
AP = 0.38
SI = 1.88; SIM = 1.26; RERI = 1.54; 
AP = 0.36
SI = 2.82; SIM = 1.79; RERI
AP = 0.46
Diabetes
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0 0 123 342 1 101 208 1 22 134 1
0 1 89 134 1.85(1.30–2.63)** 75 61 2.53(1.64–3.91)*** 14 73 1.17(0.53
1 0 52 24 6.02(3.46–10.55)*** 36 17 4.36(2.25–8.54)*** 16 7 13.92(4.69
1 1 34 10 9.45(4.33–21.12)*** 23 9 5.26(2.22–12.78)*** 11 1 67.00(
1458.0
SI = 1.44; SIM = 0.85; RERI = 2.58; 
AP = 0.27
SI = 0.87; SIM = 0.47; RERI = -0.63; 
AP = -0.12
SI = 5.04; SIM = 4.11; RERI 
AP = 0.79
Dyslipidaemia
0 0 52 327 1 47 197 1 5 130 1
0 1 35 123 1.79(1.08–2.96)* 31 57 2.28(1.28–4.05)** 4 66 1.58(0.34
1 0 123 39 19.83(12.16–
32.47)***
90 28 13.47(7.68–
23.77)***
33 11 78.00(2
287.7
1 1 88 21 26.35(14.58–
48.04)***
67 13 21.60(10.54–
45.02)***
21 8 68.25(1
282.9
SI = 1.29; SIM = 0.74; RERI = 5.73; 
AP = 0.22
SI = 1.50; SIM = 0.70; RERI = 6.85; 
AP = 0.32
SI = 0.87; SIM = 0.55; RERI 
AP = -0.15
SI, Rothman's synergy index for interaction; RERI, relative excess risk due to interaction; AP, proportion of disease attributable to interaction; *P
P > 0.05.
Table 4: Synergistic effect of ACE I/D DD genotype and classical risk factors in CAD patients and controls (Continued)
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SIM = 1.79; AP = 0.46) and ≥ 45 subgroup (SI = 4.13, SIM
= 2.36, AP = 0.65). Performing the same analysis regard-
ing diabetic individuals, significant results were found for
ACE I/D DD carriers in the whole population analysis and
a strong enhancement was found in females (SI = 5.04,
SIM = 4.11, AP = 0.79), but not in males (SI and SIM < 1,
AP < 0). None of the 2 polymorphisms presented in table
5 were found to interact with diabetes; nevertheless we
must point that all 6 individuals carrying the combination
AT1R CC and diabetes were CAD patients. The join pres-
ence of dyslipidaemia and ACE I/D DD interacts signifi-
cantly in CAD onset, except in females (SI and SIM < 1, AP
= -0.15). This combination was shown to be accountable
for 89% of the disease in the = 45 years subgroup (SI =
9.19, SIM = 9.46, AP = 0.89). All 12 individuals with AT1R
CC genotype and dyslipidaemia were found to be CAD
patients, even though no significant results were obtained
due to statistical constraint.
Discussion
Previous studies have focused on the association of any of
the ACE, AT1R and AGT gene polymorphisms with coro-
nary events of several degrees, related or not with MI and
essential hypertension. Up to know there is no consistent
genetic pattern that may link a given haplotype to the risk
of developing a CAD related syndrome or at least to make
an individual more prone to be affected. All 5 gene poly-
morphisms surveyed here promote phenotypic variants
on known mechanisms leading to changes in the bio-
chemical status of an individual. For example, the ACE I/
D variant is linked to ACE activity [10] and AGT M235T to
different angiotensinogen plasma levels [3,14].
By evaluating the distribution of RAS gene polymor-
phisms in a series of patients undergoing coronary angi-
ography, the present study has shown that only mutations
at ACE gene seem to be linked to CAD and even these are
apparently male-linked because no such association was
Table 5: Synergistic effect of AGT235 MM and AT1R CC genotypes and classical risk factors in CAD patients and controls
Classical risk factor AGT235 MM Whole population1 AT1R CC Whole population1
Hypertension CAD Controls OR(95%CI) CAD Controls OR(95%CI)
0 0 88 293 1 0 99 334 1
0 1 18 62 0.97(0.52–1.78)NS 1 7 21 1.12(0.42–2.89)NS
1 0 153 130 3.92(2.77–5.55)*** 0 182 150 4.09(2.96–5.66)***
1 1 39 25 5.19(2.88–9.41)*** 1 10 5 6.75(2.06–23.27)**
SI = 1.44; SIM = 1.36; RERI = 1.30; AP = 0.25 SI = 1.79; SIM = 1.47; RERI = 2.54; AP = 0.38
Smoking
0 0 145 315 1 0 177 356 1
0 1 37 58 1.39(0.86–2.24)NS 1 5 17 0.59(0.19–1.74)NS
1 0 96 108 1.93(1.36–2.75)** 0 104 128 1.63(1.18–2.27)**
1 1 20 29 1.50(0.79–2.85)NS 1 12 9 2.68(1.03–7.05)*
SI = 0.38; SIM = 0.56; RERI = -0.82; AP = -0.55 SI = 7.64; SIM = 2.79; RERI = 1.46; AP = 0.54
Obesity
0 0 172 352 1 0 201 394 1
0 1 42 65 1.32(0.84–2.07)NS 1 13 23 1.11(0.52–2.34)NS
1 0 69 71 1.99(1.34–2.95)** 0 80 90 1.74(1.22–2.50)**
1 1 15 22 1.40(0.67–2.89)NS 1 4 3 2.61(0.49–14.83)NS
SI = 0.31; SIM = 0.53; RERI = -0.91; AP = -0.65 SI = 1.89; SIM = 1.35; RERI = 0.76; AP = 0.29
Diabetes
0 0 171 396 1 0 201 450 1
0 1 41 80 1.19(0.77–1.84)NS 1 11 26 0.95(0.43–2.05)NS
1 0 70 27 6.00(3.63–9.98)*** 0 80 34 5.27(3.34–8.33)***
1 1 16 7 5.29(2.00–14.47)*** 1 6 0 --
SI = 0.83; SIM = 0.74; RERI = -0.90; AP = -0.17 --
Dyslipidaemia
0 0 73 370 1 0 82 424 1
0 1 14 80 0.89(0.45–1.71)NS 1 5 26 0.99(0.32–2.83)NS
1 0 168 53 16.07(10.59–24.43)*** 0 199 60 17.15(11.62–25.37)***
1 1 43 7 31.14(12.81–79.15)*** 1 12 0 --
SI = 2.01; SIM = 2.18; RERI = 15.18; AP = 0.49 --
SI, Rothman's synergy index for interaction; RERI, relative excess risk due to interaction; AP, proportion of disease attributable to interaction; *P < 
0.05, **P < 0.005, ***P < 0.0001; 1We performed no further subdivision when analysing these polymorphisms because several classes resulted 
statistically impossible to analyse due to the reduced number of individuals there included.Page 8 of 12
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type with CAD in men but not in women, has been
reported previously in several studies [27,28]. While our
patient subpopulation was in Hardy-Weinberg equilib-
rium for I/D polymorphism of ACE gene, the control sub-
population was not, due to an excess of heterozygotes ID.
Similar results were previously reported [5,29] and may
be interpreted as a case of heterosis, or even confirm the
higher risk homozygotes DD have to develop CAD.
The deletion polymorphism of the ACE gene has been
shown to be associated with both CAD and MI [5,30,31].
The mechanism by which the ACE I/D or ACE11860 gen-
otypes may predispose an individual to the development
of MI remains unclear. ACE is responsible for the conver-
sion of angiotensin I to the peptide precursor angiotensin
II, which has been implicated in the pathogenesis of
atherosclerosis [32,33]. In contrast, other studies con-
cluded that ACE polymorphisms did not influence the
development of MI or other manifestations of CAD
[34,35]. There are several possible reasons for these dis-
crepancies: besides the different genetic backgrounds of
the study populations, some of the studies cited have only
minor statistical power or the associations between ACE
gene polymorphisms and CAD or MI have been restricted
to relatively small subgroups. Even more, in some studies,
the presence or absence of CAD was not determined by
angiography and might even have used false-negative con-
trol populations. These findings also stress the necessity of
considering ethnic factors in the assessment of genetic risk
identifiers.
The total lack of association between the 2 AGTs and AT1R
polymorphisms and CAD is in agreement with other stud-
ies [14,36] that found no relation between these polymor-
phisms with CAD albeit a strong association between AGT
variants and angiotensinogen levels. Nevertheless, our
study revealed a significant influence of the A allele and
AA genotype of AT1R upon an increase in carotid-femoral
PWV values, which may be regarded as a risk factor for
CAD (results not shown).
The presence of the ACE I/D I and ACE11860 A alleles in
ACE haplotypes corresponds to the lowest risk of develop-
ing CAD in the whole population, male and female sub-
groups, expressed by ORs lower than 1. When analysing
the influence of RAS haplotypes in the development of
CAD, it is clear that the major influence comes from both
ACE polymorphisms. Yet again, the simultaneous pres-
ence of ACE I/D I and ACE11860 A alleles, corresponds to
a significant trend towards a decrease in CAD, both in
male subgroup and overall analysis. The combined set of
RAS alleles ACE11860 G/ACE I/D D/AGT174 T/AGT235
T/AT1R A was the only one found to significantly increase
CAD risk in the whole population analysis. No significant
association was found in females, showing once again the
interest of separating this type of data between sexes.
Premature CAD is known to have a particularly strong
genetic component. Previous data have suggested that
genetic factors are more likely to affect young rather than
old people [37]. We conducted a population subdivision,
analysing separately individuals who developed CAD
before the age of 45. We found no significant allele or gen-
otype association between any of the 5 polymorphisms
and early onset CAD. The only significant results were
found when associating the RAS combined set of alleles
with the disease, where individuals under 45 have a 2.47
relative risk of CAD occurrence when in the join presence
of ACE11860 G/ACE I/D D/AGT174 T/AGT235 T/AT1R A.
Here we must point the impossibility to further subdivide
this group according to sex, due to small sample size, as a
limitation to perform a more thorough analysis. One
should be aware that in almost all case-control studies,
particularly those involving haplotype analysis, problems
related to multiple comparisons (even when statistically
corrected), the potential influence of genetic and environ-
mental factors not considered, limited sample size for
subgroup analysis and the possible inclusion of patients
with silent CAD in the control group should be taken into
account. The fact that the control and CAD patients
groups are not sex and age matched may also be regarded
as a constraint in the study design.
The complex aetiology around cardiovascular disorders
and the multiple environmental conditionings are most
of the times not evaluated together. In most cases, CAD
has a multifactorial genetic basis, involving a number of
genes and environmental factors interacting to determine
whether or not the disease will develop. Therefore, the
inherited genes generally predispose to a greater or lesser
extent of CAD, but it is the environmental factors (e.g. cig-
arette smoking, obesity, hypertension, sedentarism) inter-
acting with the individual's genotype that determine
whether or not CAD will develop. We performed further
analysis in order to determine whether the simultaneous
presence of genetic polymorphisms and well established
risk factors – hypertension, smoking habit, obesity, diabe-
tes and dyslipidaemia – would enhance the effect in CAD
onset of these last. Some interesting results were obtained,
particularly in the subgroups analysis. As both ACE poly-
morphisms have shown to be in strong linkage disequilib-
rium, we chose not to show the results of this analysis for
ACE11860 GG. They are very alike those presented in
table 4 as the exact same associations were found with
similar, yet slightly lower values. We found a proportion
of CAD attributable to the interaction between hyperten-
sion and ACE I/D DD genotype around 30% for the whole
population and male subgroup analysis. In the early onset
CAD analysis, this proportion goes up to 85%. The vascu-Page 9 of 12
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are not yet fully understood. Nevertheless, a previous
study has shown a correlation between male sex and his-
tory of hypertension with serum ACE activity [38], which
may partially support our findings. This effect was also
found when considering AGT235 TT or AT1R CC as the
risk genotypes (SI = 1.44, SIM = 1.36, AP = 0.25; SI = 1.79,
SIM = 1.47, AP = 0.38, respectively). Smoking may
increase ACE levels by means of a nicotine enhancement
of ACE gene expression [39]. A large population based
study [40] found a positive association between the D
allele of the I/D polymorphism and carotid artery thick-
ness among smokers: individuals carrying only one of the
risk factors did not show significant differences in artery
thickness when compared to non-smokers with II geno-
type, while carriers of both risk factors had significantly
higher artery thickness. In our study we found a synergis-
tic effect due to smoking and ACE I/D DD join presence,
which is in accordance with a previous study [41]. More-
over, these authors found a positive association between
total high cholesterol, high LDL or overweight/obesity
and the DD genotype. In the present report we also found
this association, concerning dyslipidaemia and obesity.
This synergy effect is particularly striking when consider-
ing the early onset CAD subgroup analysis (obesity: SI =
4.13, SIM = 2.36, AP = 0.65; dyslipidaemia: SI = 9.19, SIM
= 9.46, AP = 0.89). Obesity and hypercholesterolemia
have been shown to play a role in ACE gene expression,
but also in other RAS intervenients, such as AGT or AT1R
[42]. Nevertheless, we found no association between
obesity and AGT235 TT or dyslipidaemia and AT1R CC,
even though all 12 dyslipidaemic individuals carrying
AT1R CC were CAD patients. A similar study, analysing
AGT235 T allele synergistic effect with several risk factors,
found a positive association with hypercholesterolemia
but neither with hypertension nor smoking [43]. The
association between ACE I/D polymorphism and Type 2
diabetes has been rather controversial. Some studies have
affirmed a clear association between DD genotype and the
disease in Caucasians [44] while others have excluded this
hypothesis [45]. We found a female driven synergistic
effect of DD genotype together with diabetes (SI = 5.04,
SIM = 4.11, AP = 0.79).
Conclusion
The most relevant findings of this research are based on
the influence of RAS gene polymorphisms evaluated
together with the presence of the main classical risk fac-
tors for CAD, showing how at least two polymorphisms –
ACE I/D and ACE11860 A/G – interact synergistically with
them in CAD onset. Taking into account that CAD is a
multifactorial disorder driven by numerous environmen-
tal, behavioural and genetic components interacting
together, our results seem to corroborate the hypothesis
that RAS gene polymorphisms may indeed enhance the
influence of traditional risk factors in CAD development.
The sample used in this study is also a novelty because it
is based on the population of Madeira Island that until the
beginning of the 20th century was a relatively isolated
island. To our knowledge this analysis on such a popula-
tion had not yet been performed. Madeiran inhabitants
with a history of a small founder population, long lasting
isolation and population bottleneck represent an excep-
tional resource in the identification of genes involved in
the pathogenesis of multifactorial diseases.
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